// App-Quantinova.ai

TCT-44 : LEADERS: 5-Year Follow-Up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Biodegradable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer- Final report of the LEADERS study

Researchers

Presenter

  • Patrick Serruys

Principal Investigators

  • Pawel Buszman

  • Axel Linke

  • Carlo Di Mario

  • Thomas Ischinger

  • Diethmar Antoni

  • Volker Klauss

  • Hae-Young Sohn

  • Franz Eberli

  • Roberto Corti

  • William Wijns

  • Marie-Claude Morice

Medical Centers

  • CTU Bern, Bern, Switzerland

  • American Heart of Poland, Bielsko, Poland

  • Universitat Leipzig - Herzzentrum, Leipzig, Germany

  • Universitats Spital, Zurich, Switzerland

  • Institut Cardiovasculaire Paris Sud, Massy, France

  • Heart Center Munich Bogenhausen, Munich, Germany

  • Kardiologie im Zentrum, Munich, Germany

  • Cardiovascular Center Aalst, Belgium, Aalst, Belgium

  • Thorax Center, Erasmus University, Rotterdam, Netherlands

  • Kardiologie Innenstadt, Munich, Germany

  • Medizinische Klinik - Campus Innenstadt. Klinikum der Ludwig-Maximilian-Universitaet, Munich, Germany

  • IBCSG and University Hospital, Berne, Switzerland

  • The Royal Marsden Hospital, London, United Kingdom

  • Stadtspital Triemli, Zurich, Switzerland

Locations

  • Netherlands

  • Poland

  • Germany

  • Switzerland

  • United Kingdom

  • France

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Biolimus A9

  • Rapacan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved